Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy

Haematologica

Volumn 93, Issue 11, 2008, Pages 1739-1742

  Tricot, Guido ^a   Barlogie, Bart ^b   Zangari, Maurizio ^b   Van Rhee, Frits ^b   Hoering, Antje ^c   Szymonifka, Jackie ^c   Cottler Fox, Michele ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Mobilization; Myeloma; Pegfilgrastim; Stem cells

Indexed keywords

CISPLATIN; CODEINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MORPHINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ARTICLE; BONE PAIN; CANCER CHEMOTHERAPY; CD34 SELECTION; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG FORMULATION; ENGRAFTMENT; HUMAN; MYELOMA; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; SPLEEN RUPTURE; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINS; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PLATELET COUNT;

EID: 55549109025     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13204     Document Type: Article

References (20)

1. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;2:580-5.
2. Barlogie B, Jagannath S, Vesole D, Tricot G. Autologous and allogeneic transplants for multiple myeloma. Semin Hemato 1995;32:31-44.
3. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588-96.
4. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, et al. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003;120:413-23.
5. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res 2001;7:2085-90.
6. Molineux G. The design and development of pegfilgrastim (PEGrmetHuG-CSF, Neulasta). Current Pharmaceut Design 2004;10:1235-44.
7. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas S, Jacobson J, et al. DTPACE : an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003;21:2732-9.
8. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating Bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007;138:176-85.
9. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588-95.
10. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilization in patients with multiple myeloma. Br J Haematol 2006;133:533-7.
11. Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 2006;46:180-5.
12. Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007;39:743-50.
13. Yang BB, Kido A, Shibata A. Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007;27:1387-9.
14. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, et al. Successful transplantation of stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005;35:33-6.
15. Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R, et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006;38:69-70.
16. Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G, et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005;23:8533-4.
17. Hatzimichael E, Benetatos L, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Clin Lab Haematol 2006;28:416-8.
18. Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum R. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001;97:2541-8.
19. Kröger N, Renges H, Sonnenberg S, Krüger W, Gutensohn K, Dielschneider T, et al. Stem cell mobilisation in 16 μg/kg vs 10 μg/kg of GCSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 2002;29:727-30.
20. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T, Pegfilgrastim Study Group. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003;3:391-8.